{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:49:01Z","timestamp":1768272541694,"version":"3.49.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In the double-blind (DB) ELECT study, lanreotide depot\/autogel significantly reduced versus placebo the need for short-acting octreotide for symptomatic carcinoid syndrome (CS) control in neuroendocrine tumor (NET) patients. Here we present patient-reported symptom data during DB and initial open-label (IOL) treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Adults with NETs and CS history, with\/without prior somatostatin analog use, were randomized to 16 weeks\u2019 DB lanreotide 120 mg subcutaneous or placebo every 4 weeks, followed by 32 weeks\u2019 IOL lanreotide. Patients recorded diarrhea and\/or flushing frequency and severity daily by Interactive Voice (Web) Response System for 1 month prior to randomization and throughout the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 115 patients randomized (n\u2009=\u200959 lanreotide, n\u2009=\u200956 placebo), 56 lanreotide and 45 placebo patients enrolled in the IOL phase. During DB treatment, least square (LS) mean percentages of days with moderate\/severe diarrhea and\/or flushing were significantly lower for lanreotide (23.4%) versus placebo (35.8%; LS mean difference [95% confidence interval]: \u221212.4 [\u221220.73 to \u22124.07]; p\u2009=\u2009.004). For DB lanreotide patients, average daily composite (frequency \u00d7 severity) diarrhea scores improved significantly between DB and IOL treatment (mean difference: \u22120.71 [\u22121.20 to \u22120.22]; p\u2009=\u2009.005), and remained stable for diarrhea and\/or flushing. For DB placebo patients, composite scores for diarrhea, flushing, and diarrhea and\/or flushing improved significantly between DB and IOL treatment (mean differences: \u22121.07 [\u22121.65 to \u22120.49]; \u22121.06 [\u22121.93 to \u22120.19]; and \u22122.13 [\u22123.35 to \u22120.91]; all p\u2009\u2264\u2009.018).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Improved diarrhea and flushing control in CS patients during 16-week lanreotide treatment was sustained during maintenance of lanreotide treatment for the 32-week IOL phase (48 weeks total).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>This study prospectively collected daily patient-reported data on diarrhea and flushing from the ELECT trial to evaluate the direct impact of lanreotide depot on patients\u2019 relief of carcinoid syndrome symptoms. Treatment with lanreotide depot was associated with significant reductions in the percentages of days patients reported symptoms of diarrhea and flushing, as well as reductions in the frequency and severity of daily symptoms compared with placebo during 16 weeks of double-blind treatment. These improvements were sustained for 32 additional weeks of open-label lanreotide treatment (i.e., through week 48 of treatment), resulting in clinically meaningful, long-term symptom reduction.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0284","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T01:05:19Z","timestamp":1508202319000},"page":"16-24","source":"Crossref","is-referenced-by-count":21,"title":["Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot\/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study"],"prefix":"10.1093","volume":"23","author":[{"suffix":"Jr.","given":"George A.","family":"Fisher","sequence":"first","affiliation":[{"name":"Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward M.","family":"Wolin","sequence":"additional","affiliation":[{"name":"Montefiore Einstein Center for Cancer Care, Bronx, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilani","family":"Liyanage","sequence":"additional","affiliation":[{"name":"Ipsen, Les Ulis, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Pitman Lowenthal","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals, Basking Ridge, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beloo","family":"Mirakhur","sequence":"additional","affiliation":[{"name":"Ipsen Biopharmaceuticals, Basking Ridge, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney F.","family":"Pommier","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montaser","family":"Shaheen","sequence":"additional","affiliation":[{"name":"University of New Mexico Cancer Center, Albuquerque, New Mexico, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Vinik","sequence":"additional","affiliation":[{"name":"Eastern Virginia Medical School, Norfolk, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the ELECT Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"2021122509423162500_onco12288-bib-0001","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122509423162500_onco12288-bib-0002","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"2021122509423162500_onco12288-bib-0003","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4158\/EP14464.DSC","article-title":"Aace\/Ace disease state clinical review: Diagnosis and management of midgut carcinoids","volume":"21","author":"Liu","year":"2015","journal-title":"Endocr Pract"},{"key":"2021122509423162500_onco12288-bib-0004","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bpg.2012.12.002","article-title":"Neuroendocrine tumours of the small intestine","volume":"26","author":"Strosberg","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2021122509423162500_onco12288-bib-0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","article-title":"Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center","volume":"8","author":"Janson","year":"1997","journal-title":"Ann Oncol"},{"key":"2021122509423162500_onco12288-bib-0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hoc.2015.08.006","article-title":"Clinical presentation and diagnosis of neuroendocrine tumors","volume":"30","author":"Vinik","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"2021122509423162500_onco12288-bib-0007","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2014.60.2532","article-title":"Carcinoid and neuroendocrine tumors: Building on success","volume":"33","author":"Kunz","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122509423162500_onco12288-bib-0008","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: A population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122509423162500_onco12288-bib-0009","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"suppl 7","key":"2021122509423162500_onco12288-bib-0010","doi-asserted-by":"crossref","first-page":"vii124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122509423162500_onco12288-bib-0011","author":"National","year":"2017"},{"key":"2021122509423162500_onco12288-bib-0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2021122509423162500_onco12288-bib-0013","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A Phase III Study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"2021122509423162500_onco12288-bib-0014","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"O'Toole","year":"2000","journal-title":"Cancer"},{"key":"2021122509423162500_onco12288-bib-0015","first-page":"692","article-title":"The treatment of neuroendocrine tumors with long-acting somatostatin analogs: A single center experience with lanreotide autogel","volume":"34","author":"Bianchi","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"2021122509423162500_onco12288-bib-0016","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2011.04693.x","article-title":"Long-term results of treatment of malignant carcinoid syndrome with prolonged release lanreotide (somatuline autogel)","volume":"34","author":"Khan","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122509423162500_onco12288-bib-0017","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr Pract"},{"key":"2021122509423162500_onco12288-bib-0018","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122509423162500_onco12288-bib-0019","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2021122509423162500_onco12288-bib-0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","article-title":"Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population","volume":"41","author":"Beaumont","year":"2012","journal-title":"Pancreas"},{"key":"2021122509423162500_onco12288-bib-0021","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.clinthera.2016.03.002","article-title":"Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: A qualitative interview approach","volume":"38","author":"Gelhorn","year":"2016","journal-title":"Clin Ther"},{"key":"2021122509423162500_onco12288-bib-0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2021122509423162500_onco12288-bib-0023","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/1471-2407-13-427","article-title":"Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study","volume":"13","author":"Martin-Richard","year":"2013","journal-title":"BMC Cancer"},{"key":"2021122509423162500_onco12288-bib-0024","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: An international observational study","volume":"48","author":"Ruszniewski","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2021122509423162500_onco12288-bib-0025","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122509423162500_onco12288-bib-0026","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2021122509423162500_onco12288-bib-0027","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/jco.2014.32.15_suppl.4107","article-title":"Progression-free survival (PFS) with lanreotide autogel\/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study","volume":"32","author":"Caplin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122509423162500_onco12288-bib-0028","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2017.35.4_suppl.378","article-title":"Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study","volume":"35","author":"Pommier","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122509423162500_onco12288-bib-0029"},{"key":"2021122509423162500_onco12288-bib-0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2021122509423162500_onco12288-bib-0031","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ecl.2010.12.008","article-title":"Measuring the relationship of quality of life and health status, including tumor burden, symptoms, and biochemical measures in patients with neuroendocrine tumors","volume":"40","author":"Vinik","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2021122509423162500_onco12288-bib-0032","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MPA.0b013e31819b6441","article-title":"Development of the Norfolk quality of life tool for assessing patients with neuroendocrine tumors","volume":"38","author":"Vinik","year":"2009","journal-title":"Pancreas"},{"key":"2021122509423162500_onco12288-bib-0033","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000381715","article-title":"Impact of previous somatostatin analogue use on the activity of everolimus in patients with advanced neuroendocrine tumors: Analysis from the phase III RADIANT-2 trial","volume":"102","author":"Anthony","year":"2015","journal-title":"Neuroendocrinology"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/1\/16\/41914944\/oncolo_23_1_16.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/1\/16\/41914944\/oncolo_23_1_16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T09:43:31Z","timestamp":1640425411000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/1\/16\/6438951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,10,16]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0284","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1,1]]},"published":{"date-parts":[[2017,10,16]]}}}